Notice of Receipt of the Minister of Economy, Trade and Industry Award, Japan Bio-Venture Awards
SBI Pharma Co., Ltd.
SBI Pharma Co., Ltd. (Headquarters: Minato-ku, Tokyo, Representative Director), a subsidiary of SBI Holdings Co., Ltd., which conducts research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (ALA) (* 1). Executive Officer and President: Yoshitaka Kitao, hereinafter referred to as “the Company”) received the “Minister of Economy, Trade and Industry Award” at the “10th Japan Bio-Venture Awards” (* 2) sponsored by Fuji Sankei Business i (Nippon Kogyo Shimbun). did.
The Japan Bio-Venture Award is aimed at advanced venture companies that commercialize original bio-related technologies, products, and services and strive for management. We carry out rigorous examinations from the perspectives of gender and internationality, and evaluate and commend cutting-edge and original bio-businesses.
This award is for various research and development using ALA, for example, practical application of photodynamic diagnosis (PDD) used for visualization of tumor tissue, photodynamic therapy for cancer in collaboration with domestic and overseas research institutions (PDT). ), The discovery of the effect on diabetes and the license out of the diabetes drug are considered to be highly evaluated.
We will continue to pursue various possibilities of ALA and strive for research and development so that we can provide medicines that meet unmet medical needs to as many people as possible around the world.
(* 1) 5-Aminolevulinic acid (ALA): An amino acid made by mitochondria in the body. It is an important substance that is a raw material for functional molecules involved in energy production called heme and cytochrome, but it is known that productivity decreases with aging. ALA is also found in foods such as shochu lees, red wine, and ginseng, and is also known as a raw material for chloroplasts in plants.
(* 2) Please refer to the following URL for the Japan Bio Venture Award.